DAILY BRIEF · 2026-07-16

2026-07-16

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma Verified with 1 independent source domain, 7 evidence object(s), 4 grounded fact(s), and confidence 0.80. Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress Verified with 1 independent source domain, 7 evidence object(s), 4 grounded fact(s), and confidence 0.80. Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer Verified with 1 independent source domain, 5 evidence object(s), 2 grounded fact(s), and confidence 0.80.

PHASE3 RESULT

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

Johnson & Johnson: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Confidence 0.80 · 1 source domain(s) · 7 evidence objects

PHASE3 RESULT

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

selinexor: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Confidence 0.80 · 1 source domain(s) · 7 evidence objects

PHASE3 RESULT

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

cand_6ce27a9f-a766-57cb-8594-b42fb1547a71: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Confidence 0.80 · 1 source domain(s) · 5 evidence objects

PHASE3 RESULT

Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.

Gan & Lee Pharmaceuticals.: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Confidence 0.80 · 1 source domain(s) · 6 evidence objects

PHASE3 RESULT

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

cand_cfa47cb9-7f6e-5bb7-b0a1-a10e19345ced: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Confidence 0.70 · 1 source domain(s) · 5 evidence objects